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Abstract
Background: p16INK4A expression has been used as a surrogate marker for human papillomavirus (HPV) infection in
cervical cancer and head and neck cancer. p53 has also been reported as a feasible marker to identify HPV-positive
oropharyngeal carcinoma and penile lesions. This study aimed to investigate p16INK4A and p53 expression levels
and their correlation with HPV status and clinical parameters in Kazakh patients with esophageal squamous cell
carcinoma.
Methods: Immunohistochemical expression of p16INK4A and p53 were evaluated in 163 cases of esophageal
squamous cell carcinoma in Kazakh patients. The presence of HPV DNA was detected by polymerase chain reaction.
Results: p16INK4A-positive expression was detected in 19.0 % of patients, and its expression was significantly correlated
with a lower frequency of lymph node metastasis (p = 0.038). By contrast no significant association was found between
p16INK4A-positive expression and HPV status (correlation coefficient = -0.062, p = 0.499). p16INK4A-positive expression did
not affect the odds of tumors being HPV positive (odds ratio [OR] = 0.727 with 95 % confidence interval [CI] = 0.288–
1.836). The sensitivity of p16INK4A-positive expression as an HPV marker was 0.164, with a specificity of 0.788 and a
positive predictive value of 0.391. p53-positive expression was present in 88.3 % of all cases. Although no significant
correlation with available clinical parameters was found, a significantly inverse correlation was observed between p53
expression and HPV status (correlation coefficient = -0.186, p = 0.039). Moreover, p53-positive expression decreased the
odds of tumors being HPV positive (OR = 0.292 with 95 % CI = 0.086–0.990). The sensitivity of p53-negative expression
as an HPV marker was 0.179, with a specificity of 0.940 and a positive predictive value of 0.714. The overall HPV
prevalence was high (45.5 %) in Kazakh patients, with no significant association between HPV positivity and available
clinical parameters or combined p16INK4A/p53 expression.
Conclusions: p16INK4A-positive expression was associated with lymph node metastasis. Results indicate that
p53-negative expression and not p16INK4A-positive expression may be used as a marker for HPV status in ESCC;
however, this finding requires further studies for validation.
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Background
Esophageal cancer (EC), is one of the most common
malignancies and the sixth most frequent cause of
cancer-related death worldwide with a global number
of 400,000 deaths in 2012 (http://globocan.iarc.fr/
Default.aspx). China is one of the geographical re-
gions with the highest incidence of esophageal cancer.
Of the two main histological types, the squamous cell
carcinoma (ESCC) and the adenocarcinoma (EAC),
the former is the predominant type in China account-
ing for more than 80 % of cases [1]. The Kazakh
population, which is a nomadic tribe and mainly res-
iding in Xinjiang, Northwestern China, shows higher
ESCC incidence and mortality compared with other
ethnic groups in China [2]. A better understanding of
ESCC pathogenesis for early diagnosis is crucial consider-
ing the present difficulties in detecting early symptoms,
identifying unfavourable prognosis, and low 5-year sur-
vival rate.
Human papillomavirus (HPV) are small circular
non-enveloped double-stranded DNA viruses exhibit-
ing strict epithelial tropism and infecting either mucosa
(α-papillomaviruses) or skin (β- and γ-papillomaviruses)
[3]. Several studies have demonstrated that HPV infection
is the main cause of cervical cancer and head and neck
cancer [4, 5]. HPV infection in esophageal cancer was first
reported in 1982 based on histological observations [6].
The HPV16 and HPV18 were the viral genotypes most
frequently identified in the majority of the studies [7, 8].
Few studies searched for mucosal as well as cutaneous
HPV sequences in esophageal lesions [9]. Recently it has
been reported that the HPV prevalence in ESCC of
Kazakh patients ranged from 30 % to 66.67 % [10–12]. For
such reason the identification of HPV status in the ESCC
lesions is important to establish their etiology and prog-
nostic significance [13].
HPV E6 and E7 oncoproteins are able to inactivate
p53 and pRb oncosuppressors, respectively, interfering
with cell cycle control. The oncosuppressor pRB is a
negative regulator of the cyclin-dependent kinase inhibi-
tor p16INK4A and its degradation mediated by HPV E7
causes the abnormal p16INK4A and p53 expression. Sur-
rogate markers of HPV infection are essential for cancer
screening given the low cost and high sensitivity of im-
munohistochemistry (IHC). Studies have shown that
p16INK4A expression measured by IHC correlates with
the presence of HPV DNA and thus can be used as a
surrogate marker of HPV infection in squamous cell car-
cinoma (SCC) of the cervix, vagina, and oropharynx
[14–17]. p53 has also been reported as a useful marker
for identifying HPV-positive oropharyngeal carcinoma
[18] and penile lesions [19]. However, the biomarkers of
HPV status in ESCC should be further validated to im-
prove their use for diagnosis and treatment.
This study aimed to investigate p16INK4A and p53 ex-
pression levels and their correlation with HPV status
and clinical parameters in Kazakh patients to raise the




All formalin-fixed paraffin-embedded tissue (FFPE) blocks
from 163 Kazakh patients who underwent esophagectomy
without prior chemotherapy or radiotherapy were ob-
tained from the First Affiliated Hospital of Shihezi
University School of Medicine, the People’s Hospital
of Xinjiang Uyghur Autonomous Region, and Xinjiang
Yili Prefecture Friendship Hospital in Northwestern
China from 1984 to 2013. Detailed clinical data [17]
of all the patients, including gender, age, differenti-
ation, invasion depth, lymph node metastasis, and
UICC stage (TNM stage), were also collected. The
ESCC patients were staged according to the Cancer
Staging Manual of the American Joint Committee on
Cancer. The research protocol used in this study was
in accordance with the medical ethics and human
clinical trial committee of the Shihezi University
School of Medicine, and all recruited subjects were
enrolled with written informed consent.
Tissue microarray construction
All tissues were sectioned and stained with hematoxylin
and eosin. Furthermore, the morphologically representa-
tive tissue areas of each sample identified from these
stained slides were marked. Subsequently, the fields cor-
responding to these selected regions were located in the
paraffin block for tissue microarray (TMA) construction.
1.0 mm diameter tissue cylinders were punched from
these areas of each donor tissue block and brought into
a recipient paraffin block using a homemade semi-
automated tissue arrayer (Alphelys, Plaisir, France). The
region of each tissue cylinder was reviewed to guarantee
that at least 70 % represented the typical region of inter-
est in that sample. Finally, 5 μm-thick serial sections
were prepared from the TMA blocks for immunohisto-
chemical staining.
Immunohistochemistry
Immunohistochemical staining of p16INK4A and p53
were performed using an automated immunostainer
(BOND-MAX, Leica). Slides were de-paraffinized using
a bond dewax solution (29490, Leica) and rehydrated in
absolute alcohol. Afterward, bond epitope retrieval solu-
tion 2 (ER20134, Leica) was used for epitope retrieval,
and the slides were incubated for 20 min at 100 °C and
12 min at room temperature. The slides were washed
with bond wash solution (W0080, Leica) for 3 min.
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Endogenous peroxidase activity was abolished by incu-
bating the slides for 5 min in a peroxidase-blocking solu-
tion. A total of 150 μl of the primary antibody against
p16INK4A (ZM-0205, dilution 1:500, ZSGQ-BIO) or p53
(DO-7, dilution 1:600, Gene Tech) was dropped onto
each slide, followed by incubation for 15 min. After
posting primary and polymery for 8 min each, the slides
were incubated in DAB buffer for 5 min and then
washed with distilled water. Subsequently, hematoxylin
was added onto each slide followed by incubation for
5 min. The slides were dehydrated in graded alcohol to
xylene and mounted on an anti-fade mounting medium
with mounting glass. p16INK4A-positive cervical cancer
and p53-positive esophageal cancer tissues were used as
positive controls. The data of p16INK4A immunohisto-
chemistry were available in 158 patients, whereas p53
expression was evaluable in 163 patients. Other samples
were not evaluated because of the lack of carcinoma in
the residual tissue material.
All the immunostained slides were independently eval-
uated by two experienced pathologists. Cases in which
the two pathologists disagreed on the immunostaining
results, a third pathologist was consulted to analyze the
staining. The expressions of these two markers were
scored based on cytoplasmic/nuclear staining intensity
and percentage of positively stained cells. The staining
intensity was categorized as follows: 0, negative; 1, buff; 2,
yellow; and 3, brown. The percentages of positive stained
cells were scored as follows: 0 (<5 % positive cells), 1
(6 %–25 % positive cells), 2 (26 %–50 % positive
cells), 3 (51 %–75 % positive cells), or 4 (≥76 % posi-
tive cells). p16INK4A was considered positive if strong
and diffuse staining was present in >50 % of the tumor
cells [20, 21].
The percentages of positive stained cells and the stain-
ing intensities were further multiplied to generate the
immunoreactivity score for each case and evaluate p53
expression. Four categories of expression were listed as
follow: − (a score of 0–1), + (a score of 2–4), ++ (a score
of 5–8), and +++ (a score of 9–12) [22]. p53 was consid-
ered negative when the score was between + and ++ cat-
egories, whereas the +++ score and null expression
category were considered p53 positive [18].
DNA preparation and quality control
The FFPE samples were collected in 5 μm thick sections
with 10–15 slides per sample for genomic DNA extrac-
tion using QIAamp DNA FFPE Tissue Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s
instructions. The methods used were as previously de-
scribed [23] to minimize the possibility of cross-
contamination. Subsequently, 75 % medicinal alcohol
was used to disinfect the blade before sectioning each
sample, and paraffin-only samples were cut to act as no
contamination control for every five samples. DNA ex-
traction, polymerase chain reaction (PCR) amplification,
and PCR product detection were performed in separate
spaces. As an internal control, the quality of the pre-
pared DNA was validated through PCR with a human
β-globin (forward: 5′-CAGACACCATGGTGCACCT
GAC-3′ and reverse: 5′-CCAATAGGCAGAGAGAG
TCAGTG-3′). The DNA with sufficient quality was
chosen for further study.
HPV detection
HPV DNA was detected as previously described [12].
Non-degenerate primer sets GP5+/6+ (forward: TT
GGATCCTTTGTACTGTGGTAGATACTAC and re-
verse: TTGGATCCGAAAAATAAACTGTAAATCATAT
TC) amplifying a 150 bp fragment within L1 gene of a
wide range of HPV types were used. HPV16 E7 gene
was amplified with forward primer GATGAAATA
GATGGTCCAGC and reverse primer GCTTTGTACG
CACAACCGAGC. A total of 5 μL of extracted DNA
was amplified in a final volume of 25 μL for each PCR
reaction. The reaction was performed on Life technology
under the following conditions: at 95 °C for 10 min,
followed by 40 cycles of denaturation at 94 °C for 30 s,
annealing at 42 °C for 90 s, and extension at 72 °C for
30 s, with a final extension at 72 °C for 5 min. The as-
says of the samples were run in triplicate with positive
and negative controls. Subsequently, the 10 % DNA se-
quence of the positive products was identified using
NCBI Blast (www.ncbi.nlm.nih.gov/BLAST) to confirm
the HPV type detected by PCR.
Statistical analysis
All statistical analyses were performed using SPSS
Statistics 17.0 software. Associations among p16INK4A,
p53 expression, HPV status, and clinical parameters
were analyzed using χ2-test or Fisher’s exact test.
Spearman’s rank correlation coefficients were analyzed
to investigate the possible correlations between HPV
status and p16INK4A and p53 expression levels. All statis-
tical tests were two-sided and p-values considered sig-
nificant when p < 0.05.
Results
Immunohistochemical expression of p16INK4A in
correlation with clinical parameters and HPV status in
Kazakh patients with ESCC
A total of 158 ESCC samples were analyzed for
p16INK4A expression through immunohistochemistry,
with 30 (19.0 %) and 128 (81.0 %) showing positive and
negative expressions, respectively (Fig. 1). A significant
inverse correlation was observed between p16INK4A ex-
pression and lymph node invasion (p = 0.038). Patients
with p16INK4A-positive expression had significantly less
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lymph node metastasis (35.7 % versus 57.5 %) and were
diagnosed at less advanced TNM stage, although the dif-
ference was not significant (p = 0.147). No correlation
was found between p16INK4A expression and gender, age
at diagnosis, histopathological grade, and invasion depth
(Table 1).
Although p16INK4A is used as a surrogate marker for
HPV-associated cervical cancer and head and neck
cancer, the prevalence of HPV infection in p16INK4A-
positive and p16INK4A-negative specimens demon-
strated no statistically significant difference (correlation
coefficient = -0.062, p = 0.499). p16INK4A-positive ex-
pression did not affect the odds of tumors being HPV
positive (odds ratio [OR] = 0.727 with 95 % confidence
interval [CI] 0.288–1.836). The sensitivity of
p16INK4A-positive expression as an HPV marker was
0.164, with specificity of 0.788 and positive predictive
value of 0.391.
Immunohistochemical expression of p53 in correlation
with clinical parameters and HPV status in Kazakh
patients with ESCC
A total of 163 ESCC cases were included in this analysis,
of which 144 (88.3 %) and 19 (11.7 %) exhibited p53 posi-
tive and negative expression, respectively (Fig. 1). Patients
with p53 positive expression were diagnosed at a younger
age (53.6 % versus 36.8 %) and with moderate to poor
histopathological grade (77.1 % versus 57.9 %), although
the difference was not significant (p = 0.171 and 0.070,
respectively). No correlation was detected between p53
expression and other clinical parameters (Table 2).
Fig. 1 Immunohistochemical staining of p16 and p53 in Kazakh ESCC tissues. High p16 and p53 expression levels in ESCC (A1, p16; B1, p53;
original magnification 40×). High power view (original magnification 200×) shows positive staining for p16 and p53 in the nucleus/cytoplasm and
nucleus staining of cancer cells, respectively (A2, p16; B2, p53) and p16- and p53-negative expression (A3, p16; B3, p53; original magnification 200×)
Table 1 p16INK4A expression in correlation with clinical
parameters and HPV status in Kazakh patients with ESCC
Clinical properties Total p16 expression (n/%)
Negative (%) Positive (%) P value
Gender
Male 103 85(66.4 %) 18(60.0 %) 0.507
Female 55 43(33.6 %) 12(40.0 %)
Age (mean)
< 58 85 60(48.0 %) 13(50.0 %) 0.853
≥ 58 67 65(52.0 %) 13(50.0 %)
Histopathological grade
Well 38 34(27.2 %) 4(13.3 %) 0.268
Moderate 97 76(60.8 %) 21(70.0 %)
Poor 20 15(12.0 %) 5(16.7 %)
Invasion depth
T1-T2 78 63(53.8 %) 15(51.7 %) 0.838
T3-T4 68 54(46.2 %) 14(48.3 %)
Lymphatic invasion
N0 66 48(42.5 %) 18(64.3 %) 0.038
N1-N3 75 65(57.5 %) 10(35.7 %)
TNM Staging
I/II 76 59(60.8 %) 17(77.3 %) 0.147
III/IV 43 38(39.2 %) 5(22.7 %)
HPV infection
Negative 66 52(53.1 %) 14(60.9 %) 0.499
Positive 55 46(46.9 %) 9(39.1 %)
P < 0.05 indicates a significant association among the variables
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A significantly inverse correlation between p53
expression and HPV status was found (correlation
coefficient = -0.186, p = 0.039). The prevalence of HPV
DNA in p53-negative specimens was significantly in-
creased compared with that in p53-positive tumors
(71.4 % versus 42.2 %). p53-positive expression decreased
the odds of tumors being HPV positive (OR = 0.292
with 95 % CI = 0.086–0.990). The sensitivity of p53-
negative expression as an HPV marker was 0.179,
with specificity of 0.940 and positive predictive value
of 0.714.
Correlation of HPV status with clinical characteristics and
p16INK4A and p53 expression levels
Among the 123 Kazakh patients with ESCC evaluated for
HPV status 56 (45.5 %) were found HPV-positive and 67
(54.5 %) HPV-negative (Table 3). No significant differ-
ences were observed between HPV positivity and gender,
patient age, tumor differentiation, invasion depth, lymph
node metastasis, or TNM stage.
The relationship between HPV status and p16INK4A or
p53 expression levels has been analyzed in order to iden-
tify possible associations. Previous studies reported that
high-risk HPV16 was the predominant genotype in
patients with ESCC among the Kazakh populations
[24, 25], therefore we stratified the results in HPV16
positive cases to see if there was any association with
the expression of p16INK4A and p53. Results showed that
HPV16 infection was associated with p53 (p = 0.012) but
not with p16INK4A expression (p = 0.987). Similar results
were obtained considering all HPV infections. p16INK4A
and p53 expression patterns exhibited a slight inverse cor-
relation, but this correlation was not statistically signifi-
cant (correlation coefficient = -0.061, p = 0.455, Table 4).
Furthermore, the combined p16INK4A/p53 expression
was not significantly correlated with HPV status in Kazakh
patients with ESCC (correlation coefficient = -0.077,
p = 0.420, Table 5).
Table 2 p53 expression in relation to clinical parameters and
HPV status in Kazakh patients with ESCC
Clinical properties Total p53 expression (n/%)
Negative (%) Positive (%) P value
Gender
Male 106 10(52.6 %) 96(66.7 %) 0.228
Female 57 9(47.4 %) 48(33.3 %)
Age (mean)
< 58 82 7(36.8 %) 75(53.6 %) 0.171
≥ 58 77 12(63.2 %) 65(46.4 %)
Histopathological gradea
Well 40 8(42.1 %) 32(22.9 %) 0.070
Moderate 98 8(42.1 %) 91(65.0 %)
Poor 20 3(15.8 %) 17(12.1 %)
Invasion depth
T1-T2 76 8(47.1 %) 68(51.1 %) 0.752
T3-T4 74 9(52.9 %) 65(48.9 %)
Lymphatic invasion
N0 68 6(33.3 %) 62(49.2 %) 0.207
N1-N3 76 12(66.7 %) 64(50.8 %)
TNM Staging
I/II 79 9(60.0 %) 70(64.2 %) 0.750
III/IV 45 6(40.0 %) 39(35.8 %)
HPV infection
Negative 67 4(28.6 %) 63(57.8 %) 0.039
Positive 56 10(71.4 %) 46(42.2 %)
P < 0.05 indicates a significant association among the variables
a Well differentiation vs. moderate + poor differentiation
Table 3 Correlation between HPV status and clinical parameters
in Kazakh patients with ESCC
Clinical properties Total HPV status (n/%)
Negative (%) Positive (%) P value
Gender
Male 78 42(62.7 %) 36(64.3 %) 0.855
Female 45 25(37.3 %) 20(35.7 %)
Age (mean)
<57 55 29(43.9 %) 26(47.3 %) 0.714
≥57 66 37(56.1 %) 29(52.7 %)
Histopathological gradea
Well 28 15(22.4 %) 13(23.6 %) 0.937
Moderate 77 42(62.7 %) 35(63.6 %)
Poor 17 10(14.9) 7(12.7 %)
Invasion depth
T1-T2 59 37(55.2 %) 22(40.0 %) 0.094
T3-T4 63 30(44.8 %) 33(60.0 %)
Lymphatic invasion
N0 55 28(43.8 %) 27(50.9 %) 0.438
N1-N3 62 36(56.2 %) 26(49.1 %)
TNM Staging
I/II 74 40(61.5 %) 34(65.4 %) 0.668
III/IV 43 25(38.5 %) 18(34.6 %)
a Well differentiation vs. moderate + poor differentiation
Table 4 Correlation between p16INK4A and p53 expression in
Kazakh patients with ESCC
p16- p16+ Correlation coefficient P value
p53- 14 5 -0.061 0.455
p53+ 107 25
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Discussion
We have evaluated the HPV status and p16INK4A and
p53 expression levels in ESCC from Kazakh patients.
One limitation of our study is the relative small sample
size. Nevertheless, this is among the largest studies
addressing p16INK4A and/or p53 expression and HPV in-
fection in ESCC of Kazakh population [26, 27].
The use of p16INK4A immunohistochemical analysis
as a surrogate marker of HPV infection in squamous
cell carcinoma of the cervix, vagina, and oropharynx
has been supported by many studies in recent years
[15, 17, 28–30]. The p16INK4A expression is indicative
of high risk HPV infection in cancers of squamous cell
origin [31]. In our study, patients with p16INK4A overex-
pression have a better prognosis, are correlated with less
lymph node metastasis (p = 0.038), and are frequently as-
sociated with lower-grade TNM stage (p = 0.147), which
are in accordance with previous studies [21, 26, 32].
Furthermore, p16INK4A positivity has been detected in
16.4 % of HPV-positive patients with ESCC, which is
lower than previously published data reporting a
range of prevalence between 20 % and 86.2 % [26, 33, 34].
In addition, a correlation between p16INK4A overexpres-
sion and HPV DNA positivity was previously found in
HPV-related oropharynx carcinoma [28, 29, 35]. This
association has also been previously reported in ESCC
[26, 36]. However, in the present study the p16INK4A over
expression is not associated with HPV status (p = 0.499,
OR = 0.727 with 95 % CI = 0.288–1.836). This finding is
consistent which data described in a meta-analysis [37]
and recent study [34]. The inconsistency may be explained
by the limited number of patients included in these stud-
ies and the lack of uniformity in cut-off values (different
criteria ranged from >0 % to >70 % of tumor cells dis-
playing moderate to strong staining) to define p16INK4A
overexpression. In the present study, a cut-off value of
50 %, which has been validated to correlate with the
presence of HPV in oropharyngeal SCC [16, 21], was
utilized to evaluate p16INK4A staining. The discrepant
results may also be attributed to the variation in HPV
prevalence because of different geographic areas and
ethnicity of patients [38, 39]. In addition to previously
described factors, which may influence the accuracy
of p16INK4A staining for HPV status, an aberrant
p16INK4A expression such as p16INK4A (+)/HPV(–) and
p16INK4A (–)/HPV(+) cases in various cancers exists
[15, 17, 40, 41]. Many of tumors with high p16INK4A ex-
pression were HPV-negative indicating that non-HPV
factors also lead to p16 overexpression in ESCC. The
diametrical expression of p16INK4A may be caused by
different genetic alterations. For example, 11q is fre-
quently detected to be gained in HPV-negative oropha-
ryngeal SCC, wherein Ets (a protein that can raise the
p16INK4A level) is located [15, 42]. Rb1 alterations and
subsequent p16 INK4A overexpression have also been de-
scribed in non-HPV-driven tumors [43]. Therefore, the
p16INK4A expression in HPV-negative tumors needs to
be further investigated to obtain additional information
in ESCC etiology, especially in low-incidence HPV geo-
graphic regions.
Acting as a transcription factor in cell cycle regulation,
genomic stability and apoptosis, p53 protein displays the
highest correlation with a number of cancers [44, 45].
p53 expression may be regarded as an indicator of p53
gene mutation. p53 levels are generally low or even un-
detectable under normal conditions [46]. However, p53
shows nuclear staining because of the accumulation of
mutant p53, which is resistant to degradation. Although
accumulation of p53 identified by IHC does not neces-
sarily indicate gene mutation, p53 overexpression in
most cases (85 %) implies an underlying mutation [47].
p53 has also been reported as a feasible marker for iden-
tifying HPV-positive oropharyngeal carcinoma and
penile lesions [18, 19]. In the present study, patients
with p53-positive expression were younger (p = 0.171)
and had poorer differentiation levels (p = 0.070) than
those with p53-negative expression, although these dif-
ferences were not significant. Similar to previously re-
ported data, [27, 48], these results indicate that p53 may
serve as an unfavourable prognostic marker in ESCC.
Moreover, p53 expression exhibited a significantly in-
verse correlation with HPV status (p = 0.039, OR = 0.292
with 95 % CI = 0.086–0.990), which is in accordance
with a previous study [49]. HPV-associated oropharyn-
geal SCCs generally show a low level of p53 protein be-
cause of degradation through viral E6 protein [18],
whereas HPV-negative tumors show absent or high p53
protein level because of nonsense or missense p53 muta-
tions [50]. Thus, p53 IHC may be used as a rapid, easy,
and inexpensive screening test with high specificity
(0.940) and high positive predictive value (0.714) for
HPV in ESCC. However, p53 IHC should be evaluated
in larger studies given the small number of p53-negative
patients.
HPV positivity was detected in 45.5 % of ESCC pa-
tients in this study, which is similar with previously re-
ported data in Kazakhs [10–12], with a prevalence
Table 5 Correlation between p16INK4A/p53 expression and HPV





p16+ p53+ 12 7 -0.077 0.420
p16- p53- 2 8
p16+ p53- 2 2
p16- p53+ 48 32
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ranging from 30 % to 66.67 %. No correlation was ob-
served between HPV positivity and clinicopathological
characteristics, which is in agreement with previous
studies on ESCC [51]. However this finding is not in
agreement with results obtained in cervical and head
and neck cancer patients [17, 52]. Nevertheless, several
studies have suggested that HPV mRNA detection may
differentiate active HPV infections from inactive viruses
and transient HPV contamination [53, 54]. In addition, the
correlation between HPV infection and p16INK4A and p53
co-expression did not statistically differ. Likewise, p16INK4A
and p53 expression levels have been analyzed in primary
adenocarcinoma of the urinary bladder on 36 samples. A
slight inverse correlation between p16INK4A and p53 ex-
pression was observed but without statistical significance
[31], which is consistent with the present results.
Conclusions
In summary, p16INK4A-positive expression should not be
interpreted as a reliable surrogate marker for HPV infec-
tion in Kazakhs with ESCC but can indicate lower risk
of lymph node metastasis. Our findings show that p53
expression may be a useful biomarker for diagnosis and
prognosis of HPV-positive ESCC. Nonetheless, further
studies should be performed to investigate toinvestigate
the molecular alterations of these cell-cycle related pro-
teins to elucidate ESCC pathogenesis.
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